quick read slower start weigh upon share
strong pipelin track
anoth quarter strong adjust ebitda
color fundament focu call
updat clinic catalyst horizon remain
upcom clinic catalyst could allevi pressur tibsovo
pivot readout may steal spotlight slow zynteglo
photo finish possibl til therapi pivot trial race forward
potenti de-risk clinic readout expect
look august day fda meet near-term
analyst certif import disclosur see
improv portfolio yield capit flexibl rais pt
underli margin profil improv pt
updat tipifarnib tip iceberg new
updat progress expect
top-line earn
updat ttr level sustain non-human
strong perform across board america recov
deliv solid transform continu increas
valuat high new initi potenti expand
datatim august vz/tmu result evid healthi
weak quarter guidanc challeng lt
drive growth build awar sap channel
in-lin mix pattern weigh near term
trade-rel risk turn outsiz revenu opportun
china
anoth solid quarter
europ growth invest pressur outlook long-
foundat pt
check box high qualiti earn capital-expenditure
earn surpris debt repurchas show confid
aqm continu work toward prove commerci viabil
result disappoint book surpris posit
io posit result look evid sustain
solid progress bode guidanc
quick read slower start weigh upon share
studi care june result wayfair announc larg extent look upon report
two separ announc one hand june trend track solid consist better guidanc
street forecast hand manag indic earli sept sale growth slow
june meet senior leadership next week junctur view shift lower top-
line trend wayfair shorter-term natur reflect on-going strateg shift busi time
help underpin continu sustain outsiz revenu expans compani updat estim full report
strong pipelin track
sale y/i significantli exceed our/street led strong us pump
shipment y/i continu intern expans sale adjust stock comp ebitda guidanc
rais break-even posit respect beat versu
estim came sever sourc includ higher us core pump shipment basal-iq roll-out better renew
higher ou impact anima exit line look forward key driver focu launch control-
iq build renew cycl intern expans continu believ under-appreci
sport opportun manag also note underli pump market acceler owe new technolog
help robust growth across busi unit solid contribut acg oper margin improv
adjust ebitda handili beat our/street estim revenu also came
our/street barg recoveri remain track backlog set
deliv given favor outlook manag rais guidanc call revenu
previous adjust ebitda previous rais
ebitda estim rais price target maintain outperform
anoth quarter strong adjust ebitda out-performance
adjust ebitda grew y/i far exceed estimate/consensu respect
strong pro-forma leas revenu growth y/i via price optim vap expansion/penetr valu ad
product servic furnitur rental acquisit integr cost synergi drove adjust ebitda
margin repres y/i improv
total revenu y/i outpac estimate/consensu respect us modular
segment pro-forma rental rate growth continu acceler y/i strong y/i y/i
repres seventh consecut quarter pro-forma double-digit rental revenu growth driven price
optim vap expansion/penetr strong rental rate growth high increment margin substanti
off-set us modular pro-forma unit rent decreas y/i
unsurprisingli given result compani indic expect adjust ebitda high end
origin outlook rang increas low end adjust ebitda guidanc rang
pro-forma y/i estimate/consensu reiter expect
exit adjust ebitda run-rat howev appear increment conserv
estimate/consensu respect anticip upbeat commentari compani confer call
et reiter outperform
color fundament focu call
updat clinic catalyst horizon remain sidelin
thursday aduro report result discuss recent progress manag despit trade well
cash share recov present initi phase result combin
spartalizumab view combin fail demonstr convinc activ experienc patient
may necessari rekindl investor interest aduro partner novarti continu test
multipl trial expect see new clinic updat within next month earli data compani
program iga nephropathi could give investor new hope given compani lack near-term catalyst
remain sidelin perform rate pt
upcom clinic catalyst could allevi pressur tibsovo
thursday agio report earn provid busi updat tibsovo sale quarter beat estim
vs believ recent label expans frontlin aml could drive full-year sale eu
launch tibsovo may take longer anticipateddespit file late manag expect
chmp opinion howev anticip addit expans opportun us given posit top-line data
claridhi compani expect file snda first solid tumor indic year-end key catalyst could shift
focu away tibsovo includ proof-of-concept data mitapivat beta-thalassemia earli clinic data
pivot readout may steal spotlight slow zynteglo launch
thursday bluebird report earn provid busi updat compani continu prepar
upcom european launch zynteglo believ first commerci transfusion-depend thalassemia tdt patient
could treat germani year-end believ zynteglo may repres attract option highli symptomat
tdt patient forese slow launch ramp given limit number initi plan treatment center recent
announc zynteglo value-bas price plan adjust model reflect similar price strategi
bluebird gene therapi program key clinic updat expect karmma trial believ
investor attent may refocu bluebird oncolog pipelin reiter perform
photo finish possibl til therapi pivot trial race forward
thursday iovanc announc result provid updat recent progress tumor infiltr lymphocyt til
therapi manag offer refin guidanc size trial could support registr
cervic cancer trial may enrol patient versu rang potenti put recruit on-track
complet earli manag believ develop timelin lifileucel may synchron
suggest bla melanoma cervic cancer could potenti combin singl submiss late
two pivot trial enrol next month could potenti see new data one sever on-going ist
updat respons durat data melanoma reiter outperform pt
potenti de-risk clinic readout expect
thursday syro announc earn review recent progress compani track deliv key clinic updat
year-end includ initi phase expans cohort result ovarian cancer updat phase result
azacitidin azac frontlin aml compani intend focu develop effort azac
relapsed/refractori aml set believ efficaci data newli diagnos patient could reinforc syross biomark
select strategi enrol separ cohort relapsed/refractori patient underway initi result expect
believ recent financ extend syross oper runway earli beyond critic clinic proof-of-
concept mileston reiter outperform pt
look august day fda meet near-term catalyst unev earn
cbio releas unev financi result exactli line forecast provid corpor updat includ
fda concurr newli manufactur batch marzaa equival batch use prior studi plan
conduct addit phase studi pk/pd marzaa determin time peak drug level data
reiter plan meet fda discuss phase marzaa subq factor viia studi hemophilia patient
inhibitor estim expect multipl near-term catalyst includ disclosur phase marzaa studi
design top-line data dalca phase iib studi hemophilia patient expand develop
plan marzaa
biomarin total revenu trail consensu although differ relat aldurazym
ship quarter need recogn recent account standard opex gener
line vs sg vs ep vs consensu
broadli reiter financi guidanc state track midpoint revenu non-
incom rang palynziq us commerci continu proceed admir expect
gradual eu launch look valrox us/eu regulatori submiss vosoritid phase data around year-end
price target chang earn report
report revenu beat consensu estim includ inbrija sale
estim revenu beat driven ampyra sale vs consensu updat
ampyra sale guidanc busi updat highlight improv inbrija launch dynam esrx prefer
formulari statu inbrija addit payor contract expect year-end increas high-volum prescrib
posit chmp opinion ema decis expect year-end continu pipelin develop platform
updat acut migrain financi goal posit cash flow without rais addit capit cash balanc
grow adopt inbrija encourag cautious maintain perform rate detail full report
updat tipifarnib tip iceberg new pipelin asset emerg
report ep roughli line consensu estim cash posit
support oper accord manag busi updat includ focu on-going
potenti pivot trial ptcl/aitcl trial hnscc near-term catalyst includ addit hra r/rhnscc
data run-hn mayb tripl meet registr trial hra r/rhnscc patient aim-hn could
data addit data ptcl/aitl cmml data stratifi
earli pipelin strengthen erk inhibitor data expect menin-ml inhibitor
directli start-up prepar updat model actual
updat progress expect
provid updat outlin progress toward initi studi biopsy-confirm nash patient
pre-ind packag submit face review period fda provid
feedback expect submit ind applic follow anoth fda review period could result
nash studi initi ind applic includ studi protocol expect straightforward base
recent fda guidanc nash clinic trial manag indic addit data may present
aasld updat model actual result maintain outperform rate
top-line earn
report result higher consensu revenu earn estim driven strong
hetlioz uptak lower spend despit posit growth trend patient therapi unit dispens manag
maintain revenu guidanc indic plan reassess perform howev manag increas
year-end cash guidanc importantli continu invest pursu variou
chronic episod indic tradipit await outcom litig fda relat long-term
non-human primat toxicolog studi remain sidelin tradipit regulatori legal hurdl resolv
manag howev note potenti upsid favor regulatori action hetlioz smith-mageni syndrom
updat ttr level sustain non-human primat
report result collabor revenu opex ep vs consensu ep
cash balanc manag estim fund oper call includ sever
updat pipelin in-vivo edit ex-vivo engin t-cell remain track nda submiss
attr prepar manufactur toxicolog on-going data updat show
sustain ttr reduct non-human primat month six averag reduct tcr program
progress candid nomin function test lead tcr patient-deriv xenograft model
aml on-going data lnp aav in-vivo edit approach continu impress
report adjust ep vs opco/street consensu adjust result exclud
numer item share-bas compens propos spin-off cost account larg major
produc strong result occup stay record level drive revenu out-performance vs model
drive ebitdar beat follow quarter maintain ep guidanc
tweak ep estim price target overal
busi appear well-posit spin-off recent final reg activ pipelin
continu drive stori
strong perform across board america recov improv outlook
report strong result revenu y/i handili beat street estim
improv ep cfo bill underlin healthi environ guidanc move higher
strong america perform y/i vs soft view posit wherea emea saw
tough comp temporari uk soft overal view quarter healthi acceler mix
start gener busi trend remain stabl foundat driven product refresh well secur
fabric non-fortig product among other realiz on-going solid traction custom partner
estim tweak higher outperform/pt
deliv solid transform continu increas buy-back author
post eps/revenu vs consensu estim recur revenu
increas annual recur revenu increas subscription-bas transact compris encourag
book quarter repurchas share increas buy-back author
previous highlight strategi focus consult busi higher-margin engag
drive increas softwar consumpt within target custom base depress perpetu consult revenu
still make steadi progress transform recur revenu model refocus consult
busi expand margin maintain perform rate
squar deliv solid result organ adjust revenu growth ep vs our/street
estim transact profit grew y/i vs estim subscript servic adj revenu remain
strong benefit robust app caviar capit instant deposit growth despit modest quarterli upsid
sq maintain revenu outlook continu anticip revenu growth mid-point similarli despit
quarterli upsid sq maintain ebitda expect somewhat surpris sq announc agreement
sell caviar deliveri busi doordash manag suggest would increas focu invest
capac remain encourag sq strong growth remain valuation-sensit sq trade
valuat high new initi potenti expand revenu
deliv strong result rais fy revenu guidanc stock remain weigh
high expect lower fy ebitda new initi concern could prove short-liv new free
ship program new unifi ad platform potenti view reverb marketplac use music instrument
pois bring addit growth bull like stay convinc new initi plu migrat near
complet bear worri achiev ebitda margin goal lower fy guidanc maintain
perform rate assess new initi impact result stock trade sale
high end peer group
maintain target outperform rate suit product continu expand build strateg
valu offer access avail market first time becom turnkey solut
unrepres buyer direct process offer two market expand acceler ibuy
market roll-out faster renov agent present seller instant tradit offer demand strong enough
support own partner opendoor ibuy product -- view valuat converg see signific merger
synergi real estat revenu y/i vs estim acceler manag
bullish near-term real estat demand spur lower mortgag rate better agent product
datatim august vz/tmu result evid healthi wireless backdrop
earn recap solid wireless fundament sprint share loss acceler
inxn lower estim weaker currenc slower eu economi
cloud
weak quarter guidanc challeng lt trend remain posit
boingo result continu extrem lumpi compani transit new busi lose legaci
revenu amex/retail neg normal revenu flat yoy exclud non-recur access fee revenu
contract extens adj ebitda da revenu bright spot normal
compani perfect storm see strong demand new da offload
expect add two carrier wholesal potenti reit partnership multifamili repres upsid
opportun howev reduc price target cash ebitda multipl lower estim
cash ebitda higher debt load
report result go-to-market strategi drive growth build awar
report good result assess rais guidanc highlight includ good sale execut
core-blacklin revenu growth ex-sap acceler record number larg expans deal strong
intern growth expand oper margin healthi cash gener balanc increas
invest build awar among sap salesforc could take time ramp rais estim risk
near term bottom line increas nois competit landscap think view
visionari end-market continu take share howev remain sidelin data
point go-to-market motion sap partnership scale plan maintain perform
pre-announce sale earn rang substanti consensu manag previou
guidanc manag also lower revenu guidanc yoy declin note on-going macro deterior
macro challeng intern execut issu result order push-out downsiz cancel
greatest pressur storag product largest custom apac europ public sector larg
track gm see posit lift due product mix hybrid cloud cd remain focus hybrid cloud
strategi acceler privat cloud solut cd opportun though emphas multi-quart
evolut maintain perform wait better visibl new product gain tighter execut cut estim reflect
sustain growth resourc optim
improv portfolio yield capit flexibl rais pt
connect earn re-affirmed multi-year outlook increas balanc sheet portfolio yield
sequenti deliv solid origin level activ portfolio manag shed lower-yield invest view
speak domain expertis higher-yield asset class continu matur manag continu point
robust forward pipelin invest across divers end-market capit flexibl broaden notabl
includ unsecur debt increas price target maintain outperform rate
underli margin profil improv pt
increas pt follow ep street higher gd share gain
y/i extern factor macro/european carriers/jet impact revenu y/i hybrid cloud migrat
high renew rate larger long-term contract creat better financi visibl wherebi compani reiter
ep compound-annual-growth-rate target addit higher margin revenu beat consensu strong commerci
oper see hybrid cloud migrat better posit segment key win main competitor enter
heavi renew cycl yield valuat compel stronger gd share hybrid cloud migrat
creat structur advantag gener double-digit compound-annual-growth-rate medium term maintain outperform
analyt collabor infrastructur softwar
in-lin mix pattern weigh near term
arista report solid quarter offer in-lin guidanc uncertainti durat spend paus
lift macro headwind seem develop limit upsid near-term expect share remain
range-bound near-term cloud contribut like prolif yet would point part
thesi play enterpris traction strong portfolio broadli avail campu
portfolio expect hit market given reason execut bar downsid support solidifi
repurchas program remain posit see multipl catalyst campu roll-out build
adjust estim results/guid maintain outperform pt remain
analyt collabor infrastructur softwar
drop coverag tableau softwar data previous rate perform due recent complet acquisit
compani salesforc
effect discontinu coverag last recommend associ estim reli upon
go forward data herein up-to-d last report publish june
report june sales/ep well ahead consensu sept sales/ep
outlook also best street despit beat/rais revenu outlook q/q
season outlook lower upsid larg attribut huawei management expect revenue/
gm huawei contribut sale expect vs
remaind unabl ship idp given us govern ban management remain bullish massive-mimo
adopt drive bt content attach-r like roll
well repres across equip oem huawei mimo leader exacerb near-term drag huawei uncertainti
challeng smartphon market keep us sidelin
south korean chip giant face strangl japanes export curb reuter
china huawei hit qcomm hurt ee time
intel reveal clock speed gpu spec lake mobil soc extremetech
emerg technolog servic
gopro deliv anoth solid in-lin quarter rais guidanc second consecut quarter continu channel/
inventori control solid demand posit feedback partner given compani confid head
holiday season import updat includ consolid edit app one impact recent competit
entrant better expect sell-through mid-rang line one minor import indic execut revenu
guidanc increas opex believ given momentum hero new product launch come
distanc gopro ahead competit grow track record execut investor take notic
reiter outperform maintain pt
emerg technolog servic
trade-rel risk turn outsiz revenu opportun china
report revenue/ep compar consensu
manag rais revenu guidanc vs street new mid-point
guidanc indic growth total revenu china doubl q/q account
total sale upsid surpris quarter mainli came order pull-in chines custom lg
fab enter product manag also note broad-bas strength look forward
manag believ demand remain healthi order pull-in china digest bottom line secular
growth thesi remain intact near-term macro uncertainti elev valuat keep us sidelin
quarter healthi compstore solidli line manag tick ep guidanc lower tax
interest assumpt dunkin us sale improv noteworthi believ compstore could sustain
rang digit capabl expand new innov gain traction breakfast tweak
estim incorpor guidanc expect minor chang consensu well dnkn financi target remain
intrigu would look becom construct valuat pull-back maintain perform
push past price target system sale growth acceler expect back
strengthen unit growth algorithm broad-bas upsid compstore one under-perform piec portfolio ph
receiv lot turnaround focu move forward cement best-in-class growth stori
analysi quarter allow us step ep estim also rais pt maintain
anoth solid quarter
report adjust ep penni estim essenti in-lin oper net stronger top
line slightli weaker expect margin off-set below-the-lin item mark anoth record quarter sale
adj oper incom earn includ solid y/i core growth margin expans although manag
anticip moder core growth vs first half gener stabl volum trend increment america
price effect juli sustain growth low-single-digit rang organ sale guidanc therefor
maintain clear oper momentum support margin expans overal view well
posit high-single-digit potenti low-double-digit ep growth acceler smart connect
europ growth invest pressur outlook long-term thesi remain solid
report adj ep line our/consensu estim stronger expect wi result sale
margin off-set slight miss aw importantli core order increas y/i vs challeng
stack comp support continu msd core growth narrow full-year organ growth guidanc
vs although european market soft growth invest pressur ep guidanc
view headwind temporari remain confid defens growth characterist
smart-tech adopt afford upsid multi-year om runway result mid-teen core ep compound-annual-growth-rate ad strateg
 capac rebuild believ remain uniqu posit intermediate-term earnings/cash flow
sustain growth resourc optim
dlph address structur lay growth foundat pt
dlph guidanc reflect increment light vehicl market/fx headwind acceler effort
address cost structur posit futur growth manag highlight area improv operational/capit
effici includ limit ration footprint reduc sg headcount autom basic
function reus gdi capital-expenditure migrat higher-pressur injector system modular new pe capac
match market demand announc formal plan address area could catalyst mix shift remain
near-term drag invest gdi power electron produc healthi book growth includ record pe award
quarter trim estim lower market assumpt accordingli price target move
check box high qualiti earn capital-expenditure
expect modest posit respons strong earn overal bullish updat guidanc provid
anoth reliabl high qualiti earn beat close thursday saw continu execut lower cash unit
expens loe transport compani deliv strong product
pay dividend full-year us oil product guidanc increas cash unit expens guidanc item decreas
like peer face headwind ga ngl product continu strong well result core eagl
ford delawar basin wolfcamp area drive strong corpor return roac base annual
result hope get color capital-expenditure given compani spent budget ytd
completion-heavi net til come on-lin
earn surpris debt repurchas show confid sale
gulfport provid gener in-lin result close view import take-away compani decis
tactic take advantag mispric debt earli juli pay retir debt key read-through
decis compani confid announc sale oklahoma water system later asid
topic remain slightli concern capital-expenditure guidanc gulfport spent capital-expenditure guid midpoint ytd
believ non-oper capital-expenditure may fluctuat meet capital-expenditure guidanc summar would normal expect
mute reaction report thursday sell-off news amid declin nymex henri hub ga price
anyth normal thursday volatil sell-off across industri suggest short-term relief ralli due share
 peer friday
sustain growth resourc optim
aqm continu work toward prove commerci viabil
aqm top revenu product expect manufactur cost remain elev compani
integr cost-sav adjust aquarefin process plan downtim equip install/adjust
believ continu benefit veolia experi drive commerci process import view
compani establish perform criteria clario licens agreement brought expertis
negoti financi term agreement cash hand believ aqm runway prove
target product yield cost structur guid timelin increas near-term cog assumpt per
manag discuss remain bullish believ aqm disrupt lead recycl industri
sustain growth resourc optim
result disappoint book surpris posit
miss top- bottom-lin expect maintain revenu ep guidanc compani
continu trend strong book reach ytd book juli compani book
book nearli half book believ bullish investor like look
disappoint result howev believ compani de-book interest maintain custom
relationship someth watch close expect addit custom test resili contract
light chang us trade polici aggress industri price dynam remain sidelin due concern
lt earn upsid current estim
sustain growth resourc optim
io posit result look evid sustain growth
io post upsid expect improv multi-cli revenu new ceo walk plan
process focus growth initi believ addit transpar clariti busi activ benefit
io share time continu see compani industri leader map off-shore drill believ
organ right size signific oper leverag revenu return growth io indic see six new
sanction drill project five announc project offer promis backdrop io coupl
traction compani get softwar offer remain sidelin look increment evid
revenu materi
revenu y/i consist estimate/consensu respect howev
adjust ep y/i estimate/consensu respect larg advers
use paper price higher expect cost although revenu declin across everi segment fx
driver two core segment grew organ particularli exclud advers use paper price sens
manag increment focus non-cor segment signific divestitur sooner vs later would like
well receiv consid free cash flow neg may like moder off-set stericycl
face coven limit given tough reduc guidanc modifi
estim maintain perform rate
solid progress bode guidanc achiev
deliv solid perform adjust ebitda ep free cash flow compar favor
expect adjust ebitda grew y/i exceed estimate/consensu
respect adjust ep y/i exceed estimate/consensu free cash flow
y/i top estim lower expect cash interest/cash tax expens net
total revenu y/i compar estimate/consensu respect grew
y/i organ exclud forex/fuel/post inject busi led logist segment increas y/i
transport segment impact previous announc downsiz largest custom lower truckload
rate freight brokerag favor north american ltl exhibit acceler yield growth y/i oper ratio
expand solid y/i freight brokerag net revenu margin improv y/i close new
busi annual revenu global new busi pipelin record
modifi total revenu growth guidanc y/i y/i reflect expect impact
lower truckload rate freight brokerag unfavor foreign currenc exchang favor compani updat
adjust ebitda guidanc rang y/i exist
estimate/consensu notabl increas free cash flow guidanc
larg via reduc expect cash interest cash tax expens look forward increment color
compani et confer call
august annual technolog internet commun confer bostonnext tuesday wednesday
